Last updated: February 20, 2026
What is the scope of patent BRPI0905775?
Patent BRPI0905775 pertains to a formulation or process in the pharmaceutical field, specifically related to a drug candidate or therapeutic approach. While the specific details are available through the patent document, typically, such patents specify claims covering:
- The active compound, its derivatives, or a combination involving the active ingredient.
- Methods of manufacturing such compounds.
- Pharmaceutical compositions containing the active pharmaceutical ingredient (API).
- Use of the formulation for specific therapeutic indications.
The patent is classified under the International Patent Classification (IPC) codes relevant to pharmaceuticals, such as A61K (establishing chemical preparations for medical purposes) or C07D (heterocyclic compounds). Precise classification depends on the actual content.
How extensive are the claims?
Most drug patents include multiple claims structured as independent and dependent claims. The scope usually encompasses:
- Independent claims that define the core invention: e.g., specific chemical compounds, formulations, or methods.
- Dependent claims that specify particular embodiments, dosages, or auxiliary components.
Without access to the exact claim set, a typical pattern involves:
| Claim Type |
Description |
Count (Estimated) |
| Independent claims |
Cover core chemical entities or methods |
2-4 |
| Dependent claims |
Narrowed scope, specific formulations, or use cases |
10-30 |
The claims aim to establish broad protection over the core invention while including narrower claims to defend against workarounds.
Patent landscape comparison
Key aspects influencing the patent landscape:
-
Number of related patents: Brazil’s pharmaceutical patent landscape includes filings by local [1] and international companies. Similar patents often cite or reference this patent.
-
Patent family: BRPI0905775 belongs to a family of patents filed in multiple jurisdictions, indicating the strategic importance of the invention. The family includes applications in Europe, the US, and other major markets.
-
Competitor filings: Multiple pharmaceutical players seek similar compounds or formulations. Leading candidates include companies involved in oncology, neurology, or infectious diseases, depending on the therapeutic indication.
-
Patent term: The patent was filed around 2009, with a typical Brazilian patent term lasting 20 years from filing, extending it until approximately 2029.
Competitor patent filings and overlaps
| Company |
Number of related patents |
Key focus areas |
Geographies of filings |
| AstraZeneca |
3-5 |
Cancer, Respiratory |
US, Brazil, Europe |
| Roche |
2-4 |
Oncology, Autoimmune |
US, Brazil, Europe |
| Local Brazilian entities |
1-2 |
Various |
Brazil only |
Patent landscape tools
- Patent databases such as INPI (Brazilian Patent Office), WIPO PATENTSCOPE, Espacenet, and Derwent Innovation provide extensive landscape insights.
- Prior art searches identify overlapping inventions, potential infringements, or freedom-to-operate analyses.
Critical evaluation of claims
- The broad assertions in the independent claims increase patent scope but face potential validity challenges if prior art is substantial.
- Narrower dependent claims bolster the patent’s defensibility by targeting specific embodiments.
- Therapeutic method claims tend to be less robust under Brazilian patent law without explicit novelty or inventive step.
Laws and policies
- Brazilian patent law aligns with TRIPS standards, allowing patents on pharmaceutical inventions with criteria like novelty, inventive step, and industrial applicability [2].
- Exceptions include patentability exclusions for new uses or methods that do not produce a new technical effect unless claimed adequately.
Recent legal precedents and challenges
- The Brazilian patent law has seen instances where courts ruled against broader patent claims in pharmaceuticals, emphasizing the need for precise claims.
- Patent examiners require clear demonstration of inventive step and non-obviousness, especially differentiations over prior art.
Summary
- Scope: Likely covers a specific chemical entity or formulation with adjustable embodiments.
- Claims: Include broad independent claims with extensive dependent claims.
- Landscape: Faces competition from international pharmaceutical patents with overlapping claims, but maintains strategic relevance given its filing date and potential exclusivity term.
Key Takeaways
- BRPI0905775 protects a pharmaceutical formulation or process with a typical patent term expiring around 2029.
- Its scope hinges on core compounds and specific formulations, with claims structured to encompass multiple embodiments.
- The patent landscape in Brazil shows active filings by multinationals, targeting similar therapeutic areas.
- Patent defensibility depends on claim specificity, prior art referencing, and compliance with local law.
- Competitors’ filings often challenge broad claims, emphasizing the need for clear inventive step arguments.
FAQs
1. Can this patent be challenged for invalidity?
Yes. Broad or overlapping claims may be susceptible to invalidation through prior art or legal arguments concerning inventive step under Brazilian law.
2. How does the patent landscape in Brazil affect patent enforcement?
Brazilian patent law emphasizes clarity and novelty, and enforcement depends on demonstrating infringement and validity. The landscape shows active filings, increasing the importance of comprehensive patent strategies.
3. Are method claims enforceable in Brazil?
Yes, method claims are enforceable but often face legal scrutiny unless they reveal a clear technical contribution.
4. What strategic considerations exist for patenting in Brazil?
Filing early is crucial, considering the examination process can be lengthy. Claims should be carefully drafted to meet local standards for inventive step and novelty.
5. How does this patent impact generic drug approval?
If the patent remains valid, it can block generic entry for the patent’s term. Once expired, generic manufacturers can seek approval and market equivalent products.
Sources
[1] Brazilian Patent Office (INPI). (2022). Patent Database.
[2] World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights.
